Skip to main content
. 2019 Apr 21;8(4):e01047. doi: 10.1002/cti2.1047

Figure 3.

Figure 3

Associations of serum BAFF with SLE clinical parameters. (a) Geometric mean (GM) of serum BAFF concentrations in SLE patients with inactive disease (SLEDAI‐2K ≤ 4: n = 56) versus patients with active disease (SLEDAI‐2K > 4: n = 31). (b) GM of serum BAFF concentrations in SLE patients with no flare (n = 65) versus patients with flare of disease (n = 22). (c) GM of serum BAFF concentrations in SLE patients with no organ damage (SDI = 0: n = 33) versus patients with organ damage (SDI > 0: n = 54). In a–c, horizontal bars indicate the GM (95% CI) derived from univariable linear regression analyses.